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Neural crest cells arise in the embryo from the neural plate border and migrate
throughout the body, giving rise to many different tissue types such as bones and
cartilage of the face, smooth muscles, neurons, and melanocytes. While studied
extensively in animal models, neural crest development and disease have been poorly
described in humans due to the challenges in accessing embryonic tissues. In recent
years, patient-derived human induced pluripotent stem cells (hiPSCs) have become
easier to generate, and several streamlined protocols have enabled robust differentiation
of hiPSCs to the neural crest lineage. Thus, a unique opportunity is offered for modeling
neurocristopathies using patient specific stem cell lines. In this work, we make use of
hiPSCs derived from patients affected by the Bardet–Biedl Syndrome (BBS) ciliopathy.
BBS patients often exhibit subclinical craniofacial dysmorphisms that are likely to be
associated with the neural crest-derived facial skeleton. We focus on hiPSCs carrying
variants in the BBS10 gene, which encodes a protein forming part of a chaperonin-
like complex associated with the cilium. Here, we establish a pipeline for profiling
hiPSCs during differentiation toward the neural crest stem cell fate. This can be used
to characterize the differentiation properties of the neural crest-like cells. Two different
BBS10 mutant lines showed a reduction in expression of the characteristic neural crest
gene expression profile. Further analysis of both BBS10 mutant lines highlighted the
inability of these mutant lines to differentiate toward a neural crest fate, which was also
characterized by a decreased WNT and BMP response. Altogether, our study suggests
a requirement for wild-type BBS10 in human neural crest development. In the long term,
approaches such as the one we describe will allow direct comparison of disease-specific
cell lines. This will provide valuable insights into the relationships between genetic
background and heterogeneity in cellular models. The possibility of integrating laboratory
data with clinical phenotypes will move us toward precision medicine approaches.
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INTRODUCTION
Neural crest cells are a highly migratory, multipotent stem cell
population that contributes to a broad range of tissues, including
craniofacial bone and cartilage, peripheral neurons, glia, pigment,
and other cells during embryonic development (Trainor, 2014).
Elucidating the cellular and molecular mechanisms of lineage
specification and migration of neural crest stem cells is essential
for understanding the pathogenesis of neurocristopathies, a
family of diseases caused by anomalies in the migration or
cell behavior of neural crest cells. Ciliopathies are a class of
genetic disorders characterized by mutation of proteins affecting
the structure or function of the cilium (Eggenschwiler and
Anderson, 2007; Ishikawa and Marshall, 2011). The cilium is
a microtubule-based cellular organelle crucial for cell signaling,
mechanotransduction and fluid flow, such as in airways and brain
ventricles. Loss of the cilium has been linked to craniofacial
anomalies such as micrognathia and facial clefting (Cortés et al.,
2015; Adel Al-Lami et al., 2016). Cranial ciliopathies are caused
by mutations in ciliary genes that may result from altered neural
crest cell development (Cortés et al., 2015). How neural crest
cell migration (see Tobin et al., 2008; Schock et al., 2015) is
affected by cilia defects remains to be fully explored. Bardet–Biedl
Syndrome (BBS) is a prototypic ciliopathy that can affect neural
crest-derived tissues.
BBS proteins can be categorized by their location and function
within the primary cilia, with a subset of BBS proteins forming the
BBSome (Figure 1A). The BBSome is an adaptor complex that is
crucial for cilia function (Jin and Nachury, 2009; Suspitsin and
Imyanitov, 2016). Clinical findings indicate that patients carrying
BBS mutations often present with subclinical craniofacial changes
including speech and oral phenotypes, mid-facial flattening and
some mild retrognathia (Tobin et al., 2008; Panny et al., 2017).
In addition, Bbs6 mutant mouse skulls showed a reduction in
the size of the pre-maxillary and maxillary regions (Tobin et al.,
2008). Similarly, zebrafish knockdowns of bbs4, bbs6, and bbs8
had shortened facial cartilages and mandibles correlating with a
reduction in neural crest cell migration (Tobin et al., 2008).
We focused on BBS10 due to the high prevalence of BBS10
mutations in humans, which comprises approximately 20% of
the BBS population (Stoetzel et al., 2006; Forsythe and Beales,
2013). BBS10, along with BBS6 and 12, is part of a chaperonin-like
complex which mediates the assembly of the BBSome (Stoetzel
et al., 2006, 2007; Billingsley et al., 2010; Seo et al., 2010; Zhang
et al., 2012). Phenotypes associated with BBS6, 10 and 12 are
thought to be more severe than other commonly mutated BBS
genes like BBS1 (Castro-Sánchez et al., 2015). Furthermore, bbs10
morphant zebrafish larvae exhibit shortened body axis and poor
somitic definition among other more variable phenotypes, while a
sub-phenotypic dose of bbs10 morpholino oligonucleotides (MO)
exacerbates the phenotypes observed in other bbs morphants
(Stoetzel et al., 2006). In alignment with the human disease, Bbs10
knockout mice are viable but exhibit obesity, retinal degeneration
and cystic kidney phenotypes (Cognard et al., 2015).
Together, these studies in fish and mouse suggest that BBS10
is necessary for normal cilia function, and when mutated, causes
a range of BBS phenotypes. The potential neural crest defects
observed in the knockdowns also fit generally with observations
linking ciliopathic mutations and craniofacial malformations in
humans. It is unclear what specific alterations in neural crest
cell (NCC) functions (e.g., differentiation, migration) are caused
by mutations in BBS10. To define the pathogenic mechanisms
of these mutations, we sought to model NCC induction in
BBS10 mutant iPSCs.
Human induced pluripotent stem cells (hiPSC) are a powerful
tool for the study of human developmental disorders as they
can be used to model genotype-specific molecular and cellular
phenotypes during differentiation. Over the last decade, several
protocols have been developed for neural crest cell (NCC)
induction from hiPSCs, using defined factors at specific time
points to generate “purer” cell populations which can be used to
study induction, migration and differentiation (Chambers et al.,
2013; Menendez et al., 2013; Leung et al., 2016; reviewed in Zhu
et al., 2016). The Human Induced Pluripotent Stem Cell Initiative
(HipSci1) has generated and characterized a panel of hundreds
of hiPSCs including from a significant cohort of BBS patients
hosting a diverse spectrum of mutations in genes involved in BBS.
Here, as a proof of concept, we use the recently described (Leung
et al., 2016) protocol to obtain efficient neural crest induction
and compare HipSci cell lines from healthy volunteers with two
cell lines obtained from BBS patients carrying BBS10 mutations
(Table 1). We show that both mutant cell lines have altered neural
crest induction and differentiation, demonstrating the feasibility
of using hiPSCs from ciliopathies to explore processes affecting
neural crest induction. This approach will help us to define the
human phenotypes and dissect the role of cilia during neural
crest development.
MATERIALS AND METHODS
Human Induced Pluripotent Cell Lines
(hiPSC)
Control hiPSCs and BBS patient-derived hiPSC lines harboring
mutations in BBS10, part of the ciliary chaperonin complex
(Figure 1A) were obtained from the HipSci consortium (see
Table 1). Ethical approval was obtained either from NRES
Committee East of England – Cambridge Central, Study title:
Generation of Induced Pluripotent Stem (iPS) Cells and Rare
Diseases. REC Ref: 15/EE/0049, or from NRES Committee
London-Bloomsbury, Study title: Molecular Genetics of Human
Birth Defects – mapping and gene identification. REC Ref:
08/H0713/82. hiPSCs were maintained in Essential 8 media
(Thermo Fisher Scientific, United States) on an extracellular
matrix replacement, Matrigel (Corning). XIRY was initially
obtained cultured on Matrigel whereas QOLG and LAIG,
acquired on vitronectin, were cultured on Matrigel for several
passages to ensure that all cell lines were comparable. Cells were
typically passaged twice weekly using 0.5 mM EDTA, dissociated
with gentle pipetting and analyzed between passages 30–60.
1http://www.hipsci.org
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FIGURE 1 | Continued
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FIGURE 1 | BBS10 variant hiPSCs are pluripotent and can form cilia. (A) Schematic representation of the primary cilium. AX, axoneme; BB, basal body; IFT,
intraflagellar transport. BBS1-20 proteins are depicted in their associated complex (BBSome and chaperonin) or by localization to other structures (scheme adapted
from Suspitsin and Imyanitov, 2016). (B) Schematics showing BBS10 transcript and protein structure (723AA). Regions exhibiting homology with chaperonin
domains are shown in the wildtype protein (scheme adapted from Álvarez-Satta et al., 2017). Variants from two BBS10 mutant lines XIRY (blue) and LAIG (red) are
mapped onto protein domains with comparison to control (QOLG or KEGD). (C–E) Cells were immunostained for the pluripotency marker OCT3/4. Control (QOLG)
cells and BBS10 mutants (XIRY and LAIG) all had positive staining in the nucleus. Merge with DNA dye Hoechst (C’–E’). All cells exhibit staining although there is
some variability with less intense staining being seen in the central regions of the colonies. (F–H) Staining for the ciliary axoneme marker, ARL13B was performed.
Control (KEGD) cells show positive staining for ARL13B (F). XIRY cells and LAIG cells (H) both express cilia. Merge with DNA dye Hoechst (F’–H’). Cilia frequency
was quantitated by manual counting (I). LAIG cells had a moderate increase in percentage of cells with cilia compared to control cells. XIRY cells showed no
significant difference although were more variable. P-values were determined using unpaired Student’s t-tests (∗P ≤ 0.05). Scale bars (E’,H’) = 50 µm.
TABLE 1 | Cell lines used in this study.
Donor Cell line BBS10 variant 1 BBS10 variant 2 Age Sex Ethnicity
QOLG Qolg_1 Wildtype Wildtype 35–39 Male White, British
KEGD Kegd_2 Wildtype Wildtype 40–44 Male White, British
XIRY Xiry_5 c.989T>C/p.Val330Ala c.235dup/p.Thr79Asnfs∗17 35–39 Male White, British
LAIG Laig_1 c.285A>T/p.Arg95Ser c.2119_2120del/p.Val707∗ 25–29 Female White, European
Neural Crest Induction
Neural crest induction was carried out as per (Leung et al.,
2016), which is designed to mimic normal neural crest
development (Figure 2). TrypLE Express (Thermo Fisher
Scientific, United States) was used to detach hiPSCs into a single
cell suspension. Next, 200,000 hiPSCs were plated in each well of
a 6-well plate coated with Matrigel. At the start of the induction
protocol (time = 0 h), wells were incubated with neural crest
induction medium + 10 µM Y-27632 (Cell Guidance Systems)
for the first 48 h (48 h) of culture, then in neural crest induction
media alone for the indicated time. Samples were then fixed in 4%
PFA in PBS for antibody staining or lysed in Trizol (Sigma) for
RNA extraction. Neural crest induction media is as per (Leung
et al., 2016): 50:50 DMEM:F12 (Sigma, United States), 2% B27
supplement (Life Technologies, United States), 1X L-glutamine
(Invitrogen), 0.5% BSA (Sigma), 3 µM CHIR99021 (Sigma).
Immunofluorescent Antibody Staining
After fixation, cells were washed three times in 1X PBS and then
permeabilised by incubation with 0.5% TritonX-100 (Sigma) in
1X PBS for 5 min at room temperature. Next, cells were blocked
for 1 h at room temperature [in 3% BSA (Sigma) in 1X PBS,
0.01% Tween 20 (Sigma)]. Primary antibodies (see Table 2) were
incubated overnight at 4◦C in blocking solution. Three 15 min
FIGURE 2 | Neural crest induction in vivo and in human induced pluripotent stem cells. (A) In vivo neural crest induction occurs at the border (green) between the
neural plate (blue) and the non-neural ectoderm (light pink). As neurulation progresses the neural folds begin to approximate and neural crest delaminate from the
epithelium and begin migration. (B) In vitro neural crest induction in hiPSCs following the protocol from Leung et al., 2016. hiPSCs are plated on Matrigel and treated
for 48 h in neural crest induction (NCI) media plus Rock inhibitor (RI). This is followed by incubation in neural crest induction media without RI until 120 h of culture. At
the start, pluripotency markers (OCT3/4, NANOG, and CMYC) are expressed. By 2 days of culture, neural border markers are expressed (PAX3, PAX7, TFAP2A,
ZIC1). By 5 days of culture, cells express markers of neural crest identity (FOXD3, SNAIL2, SOX10).
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TABLE 2 | Antibodies used in this study.
Antibody Targets: Concentration Supplier (catalog
number)
ARL13B Ciliary axoneme 1:500 Proteintech
(17711-1-AP)
SOX10 Migratory neural
crest
1:500 Santa Cruz
(sc-365692)
OCT3/4 Pluripotency 1:200 Santa Cruz
(sc-5279)
P75NTR Neurotrophin
receptor/neural
crest
1:600 Millipore (07-476)
Anti-mouse
488
Secondary
antibody
1:500 Invitrogen (A11001)
Anti-rabbit 568 Secondary
antibody
1:500 Invitrogen (A11011)
Anti-rabbit 488 Secondary
antibody
1:500 Invitrogen (A11008)
washes in PBS with 1% BSA, 0.01% Tween 20 were carried
out. Fluorescent secondary antibodies were diluted in blocking
solution and plates were incubated at room temperature for 1–
2 h. Next, three 15 min washes in PBS with 1% BSA, 0.01%
Tween 20 were carried out. Hoechst 33342 (Sigma), diluted at
1:1000 from a 20 mg/ml stock, was added to the first wash as
a nuclear stain.
Microscopy and Imaging
Cells were routinely viewed and imaged by phase-contrast
microscopy. Fluorescence imaging of immunostained samples
was carried out using an inverted epifluorescence microscope
(Zeiss or Olympus) with a plate stage adaptor. All image
processing was carried out in Image J. Figures were made using
Adobe Illustrator CS5.5.
Cilia quantification was manually carried out using the cell
counter plug-in of ImageJ. For these quantifications the control
line KEGD was used due to lack of QOLG line availability. In
addition, these cells were cultured on vitronectin rather than
Matrigel (Corning). The percentage of ciliated cells was calculated
from total nuclei and cilia counts manually obtained from
representative images (total number of control cells counted:
KEGD = 2631, mutant cells: LAIG = 2293 and XIRY = 1742).
Nuclei and cilia of cells touching the field edge were assessed from
contrast adjustment of the ARL13B channel and excluded.
Quantitative Reverse Transcription
Polymerase Chain Reaction (qRT-PCR)
RNA was extracted from hiPSCs, after 48 h of induction or
120 h of induction, using Trizol (Sigma) as per manufacturer’s
instructions. RNA was then DNAse I (Promega, United States)
treated. 500 ng to 1 µg of DNAse treated RNA was primed
with random hexamers (Promega) and reverse transcription
was carried out according to manufacturer’s protocol (M-MLV
Reverse Transcriptase, Promega, M1701. All qRT-PCRs were
performed using Bioline 2X Sensimix (QT605-05) using a
Roche Lightcycler 480. Quantification of each PCR reaction was
carried out using absolute standards, and normalized to β-actin
levels. See Table 3 for primers used in this study. Statistical
significance for all RT-qPCR data was analyzed using un-paired,
Student’s t-tests.
RESULTS
Comparable Culture Conditions for
Pluripotent Stem Cells
We selected several lines from the HipSci cell bank: a control
line, KEGD (cilia quantitation) and QOLG (used for the
majority of our assays) and two BBS10 mutant lines, XIRY
TABLE 3 | RT-qPCR primers used in this study.
Gene Forward primer Reverse primer
β-ACTIN AGCCTCGCCTTTGCCG CTCGTCGCCCACATAGGAAT
CMYC TTTCTGAAGAGGACTTGTTGCGGAAACGAC TCAGCCAAGGTTGTGAGGTTGCATTTGATC
NANOG TCTCTCCTCTTCCTTCCTCCATG CTGTTTGTAGCTGAGGTTCAGGATG
OCT3/4 GACAGGGGGAGGGGAGGAGCTAGG CTTCCCTCCAACCAGTTGCCCCAAAC
BRY TATGAGCCTCGAATCCACATAGT CCTCGTTCTGATAAGCAGTCAC
AXIN2 AGTCAGCAGAGGGACAGGAA AGCTCTGAGCCTTCAGCATC
PTC1 CCCCTGTACGAAGTGGACACTCTC AAGGAAGATCACCACTACCTTGGCT
SIX1 TCAGCTCCAAGACTCTCTGC ACAAGCTGCAAAAATGTTCC
SOX2 TCAAGCGGCCCATGAATGCC AGCCGCTTAGCCTCGTCGAT
TFAP2A GATCCTCGCAGGGACTACAG TACCCGGGTCTTCTACATGC
ZIC1 GTCCTACACGCATCCCAGTT GCGATAAGGAGCTTGTGGTC
MSX1 CTGCACCCTCCGCAAACACA AGGCTGAGCGAGCTGGAGAA
PAX3 AATTACTCAAGGACGCGGTC TTCTTCTCGCTTTCCTCTGC
PAX7 TGACAGCTTCATGAATCCGG GATGGAGAAGTCAGCCTGTG
FOXD3 GCATCTGCGAGTTCATCAGC CGTTGAGTGAGAGGTTGTGG
SOX10 CTCTGGAGGCTGCTGAA TGGGCTGGTACTTGTAGTC
SNAI2 CAGACCCTGGTTGCTTCAAG GAGCCCTCAGATTTGACCTG
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and LAIG. Both mutant lines carry compound heterozygous
variants (Figure 1B and Table 1). The XIRY line carries two
alleles: a non-synonymous change (V330A) on one allele, and
a duplication on the other allele that leads to a frameshift and
an early stop (T79Nfs∗17), likely to result in a loss-of-function
variant (Figure 1B). LAIG carries an allele with a synonymous
mutation (R95S) and an allele with a 2-base pair deletion leading
to a truncated protein lacking the final 16 amino acids (V707∗)
(Figure 1B). Based on these genotypes, we expect that the XIRY
variants will have a more significant impact on protein function.
Matrigel was used to wean lines for comparable results and
all cell lines exhibited an embryonic stem (ES) cell-like state,
forming tight colonies of packed cells (Figures 1C–E). Cultures
were discarded if delaminating, if differentiated cells were present
on greater than 25% of the colonies, or if large regions of
non-colony bound cells were present. We confirmed that our
culture conditions were suitable for maintaining pluripotency in
all three hiPSC lines. Immunostaining for OCT3/4, one of the
defining features of pluripotency, was carried out on all three
lines after adaptation to Matrigel. All lines exhibited positive
nuclear staining for OCT3/4 confirming the pluripotent nature of
these cells, and no significant differences were observed in BBS10
mutants compared to controls (Figures 1C–E).
Reduced Primary Cilia Expression in
BBS10 Mutant hiPSCs
Normally, a proportion of cells within hiPSC colonies express
primary cilia (Nathwani et al., 2014). To confirm that BBS10
mutant cells are still able to generate cilia, we performed
immunostaining on the hiPSCs with ARL13B, a marker of the
ciliary axoneme. We found that both control lines expressed an
abundance of cilia-specific ARL13B staining (KEGD, shown in
Figure 1F; QOLG, data not shown). Both BBS10 mutant lines also
had cells with positive staining (Figures 1G,H). Both mutant lines
expressed cilia; interestingly, quantification indicated that LAIG
and not XIRY had a slight but statistically significant increase in
the number of cilia numbers compared to control (Figures 1F–I).
Anecdotally, the percentage of cells with cilia in XIRY was very
variable (Figures 1G,I). These data suggest that BBS10 is not
strictly required for ciliogenesis, at least in the pluripotent state.
Differentiation of hiPSCs to Neural Crest
Stem Cells
To confirm that both normal and BBS10 mutant hiPSCs could
be differentiated toward the neural crest lineage, we used a 5-
day induction protocol where activation of the WNT pathway
[via inhibition of glycogen synthase kinase-3 (GSK-3)] induces
neural border genes and neural crest markers mimicking normal
neural crest development (Figure 2; Leung et al., 2016). Cells
were monitored daily and unattached cells were washed away
during media changes, leaving behind adherent colonie in control
(Figures 3A–E) and mutant cells (Figures 3F–J,K–O). At initial
plating, control and mutant cells formed small colonies with
protrusions (Figures 3A,F,K). By 24 h of culture, cells are still
present as small iPS-like colonies (Figures 3B,G,L). By 48 h of
culture, a subset of cells in the control QOLG colonies have begun
delaminating (Figure 3C, blue arrowhead). This was rarely seen
in BBS10 mutant colonies at 48 h (Figures 3H,M). In contrast,
mutant cell colonies showed delamination at 96 h of culture
(Figures 3I,N, blue arrowheads). These results suggest a delay in
neural crest induction in BBS10 mutants.
Furthermore, despite being initially plated at the same density,
fewer cells were observed in the mutant cultures over the first
72 h of culture. By day 5, most areas of cultures had reached
confluency; however, the control was visibly denser (Figure 3E).
At 120 h dense areas (yellow arrowheads, Figures 3E,J,O)
were present, and these resembled the morphology of colony-
like arrangements seen throughout the cultures. Upon close
inspection of the delaminating stage of QOLG and XIRY cells
(48–96 h, Figure 4), it was noted that XIRY cells showed fewer
protrusions from the colonies of cells at 48 and 72 h timepoints
(Figures 4D,E). At 96 h mutant cells are seen delaminated from
cell colonies (Figure 4F). These data indicate that some neural
crest induction is taking place, with cells delaminating from
control colonies earlier than mutants.
Decreased Expression of Neural Crest
Markers in Mutant Cells
During embryogenesis, the transcription factor SOX10 and the
p75 neurotrophin receptor (p75NTR) are expressed in migratory
neural crest cells. In order to determine the identity of the
induced cells, we carried out immunostaining for these markers.
By 5 days of differentiation a majority of cells showed some
level of SOX10 expression (Figure 5). The QOLG control line
showed much higher levels of SOX10 and p75NTR expression
compared to the mutant lines (Figures 5A–C). Consistent with
SOX10 association with migratory neural crest cells, cells that
most strongly expressed SOX10 were delaminated cells at the
edge of colonies (Figure 5A). We also found cells co-expressing
p75NTR and SOX10 around the periphery of control colonies
(Figures 5A–A”). In contrast, both mutant cultures had markedly
diminished expression of SOX10 and almost no evidence of
p75NTR expression (Figures 5B–C”), although levels of SOX10
were still above background (compare Figures 5D,B–C).
Gene Expression Analysis During
Induction of the Neural Crest Lineage
As noted above, the neural crest protocol is designed to first
induce a neural border state, which is necessary for subsequent
neural crest induction. In order to determine the steps at which
neural crest induction might be perturbed, we examined gene
expression profiles over the 120 h protocol. We harvested mRNA
for quantitative RT-PCR analysis at 0 h, where cells should be self-
renewing hiPSCs, at 48 h induction, at the onset of neural border
formation, and at 120 h, when cells should be expressing neural
crest markers.
To confirm the exit from pluripotency, we first analyzed
the expression of CMYC, NANOG, and OCT3/4, which should
become progressively reduced during the 120 h period. Indeed,
these markers diminished as predicted in both QOLG and
XIRY; however, it is worth noting that XIRY cultures exhibited
a significantly higher level of all three pluripotency markers
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FIGURE 3 | Neural crest induction is delayed in BBS10 mutant cells. Phase contrast images of taken during neural crest induction at specified time points. Control
QOLG (A–E), mutant XIRY (F–J), and LAIG (K–O) cells. Discrete iPSC-like colonies can be seen at 24 h in all rows (B,G,L). In control cultures, cells are seen
delaminating from colonies at 48 h (blue arrowhead, C); whereas mutant cultures start showing delamination at 96 h (blue arrowheads, I,N). By 120 h there are still
some dense, colony-like regions present in all cultures (yellow arrowheads, E,J,O). Scale bars = 50 µm.
FIGURE 4 | Delaminated neural crest cells have a mesenchymal morphology. Phase contrast images of differentiating hiPSCs cultures taken during neural crest
induction at specified time points. Control QOLG (A–C), mutant XIRY (D–F). Note that control QOLG cells at 48 h (A) exhibit delaminated cells with mesenchymal
morphology, in contrast to XIRY cells which do not show cell delamination until 96 h (F). Scale bars = 200 µm.
at the outset, including surprisingly higher levels of NANOG
and OCT3/4 at 48 h (Figures 6A–C). Interestingly, LAIG also
expressed higher levels of OCT3/4 at the iPSC period but not
NANOG or CMYC (Figure 6C). By 120 h of culture, both lines
had almost no expression of pluripotency markers. Nevertheless,
the delayed loss of pluripotency markers could be indicative of a
failure to respond to signals that induce the neural plate border.
We then examined expression of neural plate border markers,
including PAX3, PAX7, TFAP2A (Figures 6D–F). As expected,
the control line showed an increase in all three neural plate border
markers over time, with steadily increasing levels at 48 and 120 h.
In contrast, while there was some increase in all three markers
at 48 h in XIRY compared to the start of the induction, neither
PAX3 nor PAX7 reached the higher levels achieved in QOLG
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FIGURE 5 | BBS10 mutant cells express lower levels of SOX10 and P75NTR
after neural crest induction. Immunostaining for the neural crest markers
SOX10 (A–C) and P75NTR (A’–C’). Control QOLG (A) cells had high levels of
SOX10 and P75NTR. BBS10 mutant cells [XIRY (B) and LAIG (C)] had
significantly lower levels of both markers. Merge with DNA dye Hoechst
(A”–C”). No positive staining was observed in the no primary control for
SOX10 or P75NTR (D–D”). Scale bars = 50 µm.
at 120 h (Figures 6D–F). LAIG also fails to upregulate neural
plate border markers PAX3 and TFAP2A (Figures 6D–E). For
technical reasons, we were unable to assess PAX7 expression in
LAIG. Together, this demonstrates that induction of the neural
plate border genes is not delayed, and is instead unable to
reach the levels attained in controls. Altogether these results
are strongly indicative of a failure to respond appropriately to
inductive signals.
When we examined expression of the neural crest markers
FOXD3, SOX10, and SNAIL2 by qPCR, we found a profile similar
to that of the neural border markers. While there was induction
of all three genes during the differentiation protocol, expression
levels in both mutant cell lines were significantly lower compared
to control (Figures 6G–I). It is worth noting that prior to neural
crest induction, LAIG expressed significantly higher levels of
FOXD3 (Figure 6G), which was lost by 48 h of induction. This
raised the possibility that the mutant cell lines responded to the
differentiation protocol via induction of a non-neural crest state.
Note that we see some moderate induction of neural border and
neural crest markers in XIRY.
Surprisingly, we found that XIRY expressed significantly
higher levels of the mesodermal marker Brachyury (BRY) by
2 days of culture (Figure 7A). SOX2 expression is an early
marker of pluripotency (during the hiPSC stage) and then
becomes a marker of neural tissues. Consistent with this, control
QOLG cells express SOX2 initially (0 h), followed by a peak at
neural border stages (48 h) and a dip as neural crest induction
progresses. In contrast, we found that XIRY cells had normal
levels of SOX2 initially, but this decreased significantly by day
5 of culture (Figure 7B). SOX2 expression in the mutant LAIG
was significantly lower during pluripotency stages, but responded
normally to induction.
We next examined two markers of the pre-placodal ectoderm
(PPE). Similar to the neural crest lineage, the pre-placodal
ectoderm also relies on the appropriate induction of the neural
border. ZIC1 marks both the neural border and subsequently
the PPE, and in controls, can be seen increasing over the
course of the 5-day protocol (Figure 7C). To our surprise, ZIC1
is significantly higher in XIRY mutant cells at 48 h but this
trend is not continued, and levels of ZIC1 in the mutant are
significantly lower by 5 days of culture (Figure 7C). At all
stages throughout induction, expression of ZIC1 was significantly
reduced in mutant LAIG. Sustained ZIC1 expression is necessary
for activation of pre-placodal ectoderm genes such as SIX1 (Hong
and Saint-Jeannet, 2007); consistent with this, in XIRY, there is
only a minimal increase of SIX1 expression at 5 days compared
to controls (Figure 7D). For technical reasons, we were unable to
compare SIX1 levels in LAIG.
Given the importance of BMP and WNT signals during
specification of the neural plate border and subsequently in
induction of the neural crest and pre-placodal lineages, we
hypothesized that the mutant line had a dampened response to
these key signals. To test this, we examined expression of the
Wnt-responsive gene Axin2 and the BMP-responsive gene MSX1
(Figures 7E,F, respectively). Consistent with reports from Leung
et al. (2016) we saw a graded increase in AXIN2 expression
in the control line QOLG during induction (Figure 7E). Both
mutant lines showed drastically lower expression of AXIN2 by
5 days of culture (Figure 7E). Similarly, the BMP-responsive gene
MSX1 failed to be up-regulated in the mutant lines (Figure 7F).
Due to the crucial role for cilia in Hedgehog (Hh) signaling,
we also examined the Hh target Patched1 (PTC1). There was
generally no significant difference between control and mutant
lines; however, mutants did show some variable increase early
in induction (Figure 7G). This could indicate a lack of ciliary-
mediated processing of the GLI repressors. Taken together, these
data suggest that a failure in signal responsiveness in mutant cells
underlies the observed neural crest induction phenotype.
DISCUSSION
Neurocristopathies, or diseases of the neural crest lineage, were
first considered collectively by Bolande (1974). Since then, it has
become clear that these disorders encompass a broad variety
of diseases (Vega-Lopez et al., 2018). Due to the diversity of
neural crest derivatives, mutations affecting this lineage lead to
many pleiotropic phenotypes. Furthermore, the assimilation of
the neural crest lineage into multiple organ systems makes it
particularly difficult to assess function of this lineage in vitro.
Therefore, recent advances in human-derived cellular approaches
offer new tools for the study of complex human conditions. To
be able to best use these patient-derived cells, there is an acute
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need to establish streamlined, robust and reproducible assays to
test each step of neural crest formation. In this work, we used the
short neural crest induction protocol developed by Leung et al.
(2016) to determine key requirements for a disease gene in neural
crest stem cell pathology.
The long-term goal of a project such as this is the ability
to model “disease in a dish,” using the patient’s own cells to
understand the underlying cellular and molecular causes of
pathology or using the patient’s cells to design new therapeutics.
This approach complements existing animal models, which are
very powerful for in vivo studies, but often do not entirely
recapitulate the human condition. For example, genetic knock-
outs of crucial genes frequently lead to embryonic lethality.
However, it is clear from disorders such as BBS, that the human
disease variants are often of unknown function and difficult to
study without a clear cellular or molecular assay. Furthermore,
genes such as BBS10 lead to a broad range of phenotypes in
patients, including different manifestations from sibling to sibling
(carrying the same variant). This variability also complicates our
understanding of gene-function interactions.
To truly link gene identity to gene function using animal
models, it would be necessary to generate “humanized” models:
e.g., knock-ins of human disease gene variants. This is clearly
not feasible in most cases, and, may not truly reflect the human
condition due to genetic background. While use of hiPSCs
to complement animal models has become more common in
FIGURE 6 | Dynamics of pluripotency, neural plate border and neural crest marker expression during neural crest induction. Neural crest induction was carried out
on control QOLG (blue), mutant XIRY (purple), and LAIG (orange) hiPSC lines. Cells were harvested for RNA before plating (iPSC, time = 0 h), at 48 and 120 h of
differentiation. RT-qPCR analysis was carried out for pluripotency markers [CMYC (A), NANOG (B), and OCT3/4 (C)], neural border identity [PAX3 (D), TFAP2A (E),
and PAX7 (F)] and subsequently markers of neural crest identity [FOXD3 (G), SNAIL2 (H), SOX10 (I)]. P-values were determined using unpaired Student’s t-tests
(∗P ≤ 0.05, ∗∗P ≤ 0.001, ∗∗∗P ≤ 0.0001).
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FIGURE 7 | BBS10 mutant line XIRY is skewed toward the mesodermal fate and has diminished WNT and BMP responsiveness. Neural crest induction was carried
out on control QOLG (blue), mutant XIRY (purple), and LAIG (orange) hiPSC lines. Cells were harvested for RNA before plating (iPSC, time = 0 h), at 48 and 120 h of
differentiation. (A–D) RT-qPCR analysis for a mesodermal marker, BRY (A), a neural marker, SOX2 (B), neural border/pre-placodal marker, ZIC1 (C) and pre-placodal
marker SIX1 (D). Note the increased levels of BRY (A) and decreased levels of ZIC1 (C) and SIX1 (D) in XIRY. (E–F) RT-qPCR analysis for AXIN2 a transcriptional
target of WNT signaling (E), MSX1, a transcriptional target of BMP signaling (F) and PTC1, a transcriptional target of Hedgehog signaling (G). (E) Note transient
increase in AXIN2 expression in XIRY from 0 to 48 h, but a decrease by 120 h. (F) Note a failure to activate MSX1 expression in XIRY and LAIG compared to control
QOLG. (G) Note variability of PTC1 expression in XIRY at 0 h and both mutants at 48 h. P-values were determined using unpaired Student’s t-tests (∗P ≤ 0.05,
∗∗P ≤ 0.001, ∗∗∗P ≤ 0.0001).
recent years [e.g., with CHD7 patients (Okuno et al., 2017)],
there has not yet been an effort to systematically screen
candidate neurocristopathy patients. Although this study is
only focused on two BBS10 mutant lines, our work clearly
illustrates the power of defined protocols to link gene variation
to gene function.
Bardet–Biedl Syndrome 10 is a ciliopathy gene, and is one of
the most common genes mutated in BBS. Despite our knowledge
of multiple BBS human disease variants, it has been difficult
to understand the direct causative mechanisms underlying the
human condition. An established differentiation protocol such
as the neural crest induction assay is an important tool that will
allow us to dissect out the gene variants that are pathogenic. As
the CRISPR/Cas9 approaches become more efficient, we should
be able to selectively repair the BBS variants in these lines,
or to generate “disease” variants in control lines. Alternatively,
over-expression analysis with a wildtype construct might be
sufficient to rescue this neural crest induction phenotype, while
overexpression with different variants would allow us to test
specific mutations for gain- or loss-of-function during neural
crest induction. This will allow us to directly compare the
effect of different variants on the same genetic background
in order to help us begin to understand the pleiotropic
effects seen in humans.
Applications of an assay such as this one are also broad.
We can use this protocol to understand both the cellular
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and molecular profiles of patient specific cells. For example,
when Leung et al. (2016) initially developed the short-term
protocol, they tested the requirements of fibroblast growth
factor (FGF) and bone morphogenetic protein (BMP) signaling
during the induction phase. They noted that excessive levels
of FGF led to increased mesodermal specification, while BMP4
supplementation led to increased non-neural ectoderm. In
contrast, BMP inhibition reduced the levels of SOX10 positive
neural crest cells. As BBS10 is a key ciliopathy gene, and
the cilium can serve as a node for signal transduction,
it was conceivable that the phenotypes seen in our BBS10
hiPSCs were due to an inability to respond to the appropriate
inductive cues. As the main driver of the neural crest induction
protocol in this assay is Wnt activation via GSK3 inhibition,
our key finding here suggests that the ciliopathic hiPSCs
have a diminished ability to respond to the GSK3 inhibitor
CHIR99021, which is included throughout the induction
protocol. Indeed, the XIRY line initially responded to CHIR99021
by upregulating the Wnt target gene AXIN2 modestly; however,
further treatment did not recapitulate the upregulation seen
in QOLG at 120 h (Figure 7E). XIRY also fails to activate
expression of the BMP target gene MSX1. At this point, it is
unclear whether XIRY is unable to respond, or whether there
is another overriding signal. In the long-term, a molecular
analysis such as RNAseq would be a more thorough way
to compare responsiveness of wildtype and mutant cells.
Nevertheless, our findings provide an intriguing starting point
for understanding the inductive cues necessary for neural
crest development.
To our knowledge, our study is the first exploration of
the requirements for ciliopathy genes in human neural crest
development. Our findings correlate with previous observations
regarding BBS function in zebrafish models of neural crest
development (Tobin et al., 2008), and suggests a potential
role for cilia genes during establishment of the neural plate
border and induction of the neural crest lineage. Having
established this pipeline, these assays can be optimized to probe
some key characteristics of neural crest cells. For example,
two of the defining features of neural crest cells are the
prodigious migratory capacity and the multipotency. Endpoint
and live high-content imaging assays can be developed using
these read outs. As we can already see from our studies,
BBS10 mutant cells have very different morphology, protrusive
activity and migratory capacity (data not shown). In fact,
some ciliopathies, including BBS, have been associated with
Hirschsprung’s disease, which is characterized by a failure of
migration in neural crest-derived enteric neurons (de Pontual
et al., 2009). We expect to be able to synchronize our
cell populations to readily and directly compare the cellular
behaviors (as in Wiseman et al., 2019). With regards to the
differentiation capacity of neural crest, it should be immediately
possible to adapt these cultures toward the differentiation
of the diverse cell types produced by the neural crest,
including bone, cartilage, adipocytes, neurons, pigment and
other cell types.
Overall, the use of patient derived hiPSCs for the
modeling of neurocristopathy phenotypes can elucidate the
requirement of specific genes at crucial points of neural
crest development. This human genetic background specific
approach in combination with animal models will lead
to a greater understanding of mammalian neural crest
development and disease.
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